LOS ANGELES--(BUSINESS WIRE)--Hythiam, Inc. (NASDAQ:HYTM) announced the final results of two double-blind, placebo-controlled studies that help complete the Company’s data set on the impact of the PROMETA® Treatment Program (PROMETA) on alcohol dependent subjects. The first set of results includes data from the full 14-week double-blind, placebo-controlled study conducted by leading alcoholism expert Raymond Anton, M.D., of Medical University of South Carolina. Initial 6-week topline results were released by Dr. Anton at the RSA conference held in Washington, D.C. in June 2008. At week 14, the data demonstrated statistical significance for key endpoints for subjects with greater symptoms of withdrawal as measured by higher Clinical Institute Withdrawal Assessment (CIWA) scores. The higher-CIWA PROMETA subjects maintained statistical significance for endpoints that included percent days abstinent and craving, when compared to placebo subjects. The second set of results includes data from an 8-week, double-blind, placebo-controlled study on alcohol dependent subjects, all with low CIWA scores, that was recently completed by Joseph Volpicelli, M.D., Ph.D. at the Institute of Addiction Medicine. Results from this study demonstrated that, for lower-CIWA subjects with a clinical history of alcohol withdrawal symptoms, the PROMETA group experienced statistically significant decreases in alcohol craving and alcohol consumption, as compared to placebo. In addition, across the entire intent-to-treat sample, differences favored the PROMETA group.
